Prospective Observational Study of Filgotinib in Participants With Rheumatoid Arthritis in France

Active, not recruitingOBSERVATIONAL
Enrollment

155

Participants

Timeline

Start Date

May 3, 2022

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2025

Conditions
Rheumatoid Arthritis
Interventions
DRUG

Filgotinib

Tablets are administered in accordance with the product label

Trial Locations (17)

31000

CHU Toulouse, Toulouse

33000

CHU Bordeaux, Bordeaux

37044

CHRU de Tours, Tours

42000

Centre Hospitalier Universitaire de Saint Etienne, Saint-Etienne

45100

Centre Hospitalier Régional d'Orléans, Orléans

46005

CH de Cahors, Cahors

51092

Hopital Robert Debre, Reims

59037

Hopital Roger Salengro, Lille

69300

Clinique de l'Infirmerie Protestante de Lyon, Caluire-et-Cuire

75012

Hopital Saint Antoine, Paris

75014

Hopital Cochin Service A, Paris

76000

CHU de Rouen, Rouen

80054

CHU Amiens Picardie site Nord, Amiens

CHU de Amiens Picardie, Amiens

91106

Hopital Sud Francilien Corbeil Essonne, Corbeil-Essonnes

93000

Hopital Avicenne AP-HP, Bobigny

06000

CHU de Nice, Nice

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Alfasigma S.p.A.

INDUSTRY

NCT05323591 - Prospective Observational Study of Filgotinib in Participants With Rheumatoid Arthritis in France | Biotech Hunter | Biotech Hunter